Search

A new era in cancer research! Notable decision in the Official Gazette - Kayseri News

Translated title. Original: Kanser araştırmalarında yeni dönem! Resmî Gazete’de dikkat çeken karar - Kayseri Haber

A regulatory change establishes four cancer-focused scientific boards at the Turkey Cancer Institute to guide research priorities, evaluation, and development of therapies, diagnostics, and collaborations, without altering current patient treatments.

Reed Jobs’s Yosemite raises $350 million second fund to make cancer non-lethal | Fortune

Reed Jobs aims to make cancer non-lethal through a combination of venture investing and scientific grants via Yosemite, his cancer-focused fund. The firm has closed a $350 million second fund and counts major biopharma and academic LPs, pursuing long-term, multi-faceted approaches rather than a single cure.

The MFCR Congrats Drs.Taube and Szalay on AstroPath’s Selection for Anthropic’s AI for Science Program - OncoDaily

The Mark Foundation for Cancer Research congratulates Janis Taube and Alexander Szalay for AstroPath being selected for Anthropic’s AI for Science program, noting AstroPath’s cancer-imaging maps and its ties to Johns Hopkins centers; the program expands to foundations and research institutions.

If AI Can Cure Cancer, Is It Okay to Sacrifice Our Health Now? Weighing Hope Against Reality | LifeMosaic Magazine

Translated title. Original: AIががんを治すなら、今は健康を犠牲にしてもいいのか？期待と現実を考える｜LifeMosaic Magazine

AI may improve parts of cancer care, but a universal cancer cure remains uncertain, and access and clinical proof are still issues. The article argues that faith in future medicine is no reason to discount smoking risks or delay steps to protect health today.

Artificial intelligence in oncology: advances and challenges

Translated title. Original: Inteligência artificial na oncologia: avanços e desafios

The document discusses how AI, robotics, and related technologies are shaping oncology, from diagnostics and surgery to drug development, emphasizing integration of AI with imaging and genomics while noting the need for validation, clinical trials, and regulatory oversight.

Mihailo Jovanovic on X: "everyone wants AI to cure cancer 57% of AI drugs in clinical trials are cancer drugs. 80% are small molecules more drugs that can stop a heart than ever. we're engineering that part out 🧵" / X

The post says about 9,000 cancer drugs are in development, making up roughly 40% of pharma’s work. It warns that small molecules, including many kinase inhibitors, can harm the heart and notes that new drugs have been screened for rhythm risks since 2005.

Micron beat, Nvidia distancing: Moderna stock with incredible annual performance – and now? - DER AKTIONÄR

Translated title. Original: Micron geschlagen, Nvidia distanziert: Moderna-Aktie mit unglaublicher Jahresperformance – und nun? - DER AKTIONÄR

Moderna has led stock gains amid AI-driven market strength, outpacing peers like Micron and Nvidia. The company’s mRNA vaccines and expanding pipeline, including oncology and rare diseases, drive investor interest ahead of its November 6 earnings, with potential updates on influenza vaccines and oncology prospects detailed in AKTIONÄR 45/2026.

AI is changing cancer treatment — and a new breakthrough shows just how far we've come | Tom's Guide

AI tools are helping researchers analyze tumor differences, predict drug responses and speed early drug research. A Phase 3 trial found that a personalized melanoma vaccine combined with Keytruda reduced recurrence or death risk, though the vaccine is not FDA-approved.

Anthropic uses AI Claude in cancer drug research: preclinical results and a forecast for the next 10 years.

Translated title. Original: Anthropic gebruikt AI Claude in onderzoek naar kankermedicijnen: preklinische resultaten en een prognose voor de komende 10 jaar.

Anthropic reports early preclinical work using Claude to support research into cancer, food allergies and rare childhood muscle diseases. The results may help researchers screen candidates faster, but any treatments must still pass human trials and extensive testing.

Anthropic CEO Shocks: “Cancer Will Be a Thing of the Past Thanks to AI.”

Translated title. Original: Generální ředitel společnosti Anthropic šokuje: „Rakovina bude díky umělé inteligenci minulostí.“

Anthropic is using AI to support research into cancer treatments, food allergies and rare diseases. Early results are preclinical, and any candidates must still prove safe and effective in human trials, despite CEO Dario Amodei’s prediction that cancer could be overcome within 10 years.